Viagra Monitoring Schedule: Labs & Exams

How Sildenafil Works: The PDE5 Mechanism

Sildenafil blocks phosphodiesterase type 5, the enzyme that degrades cyclic guanosine monophosphate (cGMP) in the corpus cavernosum. That single action explains both why the drug works and why monitoring matters.

cGMP and Smooth Muscle Relaxation

During sexual arousal, nitric oxide (NO) is released from cavernosal nerve terminals and endothelial cells. NO activates guanylate cyclase, which produces cGMP. Rising cGMP levels relax vascular smooth muscle, allowing arterial inflow into the penile sinusoids 1. PDE5 normally breaks down cGMP within seconds. By inhibiting PDE5, sildenafil prolongs the NO-cGMP signal, sustaining erection in response to stimulation.

Why the Mechanism Demands Cardiovascular Screening

PDE5 is not limited to the penis. It is expressed in pulmonary vasculature, systemic arterioles, and platelets 2. Sildenafil produces a modest systemic blood pressure drop of 8 to 10 mmHg systolic and 5 to 6 mmHg diastolic in most men 3. That effect is clinically trivial in a normotensive man. It becomes dangerous when combined with organic nitrates, which also feed the NO-cGMP cascade, potentially producing profound, refractory hypotension 4.

Onset, Peak, and Duration

Sildenafil reaches peak plasma concentration in roughly 60 minutes on an empty stomach, with a terminal half-life of 3 to 5 hours 3. High-fat meals delay absorption by approximately 60 minutes and reduce peak levels by 29% 3. This pharmacokinetic profile shapes the monitoring window: hemodynamic effects peak within the first 1 to 2 hours post-dose.

Baseline Labs Before Starting Sildenafil

No physician should prescribe sildenafil without first understanding a patient's metabolic and hormonal field. Erectile dysfunction is frequently the first clinical sign of cardiovascular disease, diabetes, or hypogonadism 5.

Fasting Lipid Panel

The 2018 AHA/ACC cholesterol guidelines identify ED as a "risk-enhancing factor" that can tip a borderline patient toward statin therapy 6. A fasting lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides) at baseline catches dyslipidemia that may be driving both the ED and subclinical atherosclerosis.

Glycemic Markers

HbA1c or fasting glucose is required. In a cross-sectional analysis of 31,027 men from the Health Professionals Follow-Up Study, men with type 2 diabetes had a 32% higher prevalence of ED compared to age-matched controls 7. Undiagnosed diabetes changes the treatment conversation entirely: glycemic control may partially restore erectile function independent of PDE5 inhibition.

Testosterone Panel

Total testosterone and free testosterone should be drawn fasting, before 10 a.m. The Endocrine Society's 2018 guideline defines hypogonadism as total testosterone below 300 ng/dL on two morning samples 8. A man with both low testosterone and ED may respond poorly to sildenafil alone. As Dr. Shalender Bhasin, lead author of the Endocrine Society guideline, has stated: "Testosterone replacement in men with hypogonadism improves sexual desire and may augment the response to PDE5 inhibitors" 8.

Renal and Hepatic Function

Serum creatinine (with eGFR) and a hepatic panel identify patients who need dose adjustment. The FDA label recommends a 25 mg starting dose in men with creatinine clearance <30 mL/min or hepatic impairment (Child-Pugh A or B) because reduced clearance raises sildenafil exposure by 100% 3.

Cardiovascular Risk Stratification

Erectile dysfunction and cardiovascular disease share the same endothelial pathology. The Princeton III Consensus guidelines stratify men with ED into low, intermediate, and high cardiac risk before clearing them for sexual activity and PDE5 inhibitor use 9.

Low-Risk Category

Men with fewer than 3 major cardiovascular risk factors, well-controlled hypertension, mild stable angina (CCS class I), or successful revascularization more than 6 to 8 weeks prior. These patients can start sildenafil without additional cardiac testing 9.

Intermediate-Risk Category

Men with 3 or more risk factors, moderate stable angina (CCS class II), or a recent cardiovascular event within the past 2 to 6 weeks. The Princeton III panel recommends exercise stress testing or cardiology referral before prescribing. A man who can achieve 5 to 6 METs on a treadmill without ischemia or arrhythmia is generally safe for both sexual activity and sildenafil 9.

High-Risk Category

Unstable angina, uncontrolled hypertension (systolic >170 mmHg or diastolic >100 mmHg), recent MI within 2 weeks, high-risk arrhythmias, or NYHA class III to IV heart failure. Sexual activity and PDE5 inhibitors are deferred until the cardiac condition is stabilized and reassessed 9.

The First Prescription Visit: What to Check

The initial visit is the most lab-intensive. After this, monitoring requirements lighten considerably.

Blood Pressure Measurement

Resting seated blood pressure, measured with proper cuff sizing. Sildenafil is contraindicated if resting systolic pressure is below 90 mmHg 3. For men on alpha-blockers such as tamsulosin or doxazosin, a 4-hour dosing separation is recommended, and blood pressure should be stable on the alpha-blocker regimen before adding sildenafil 3.

Medication Reconciliation

This is non-negotiable. The prescriber must confirm the absence of organic nitrates (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate) and recreational nitrite ("poppers") use. A 2002 report documented 522 sildenafil-associated deaths reported to the FDA between 1998 and 2001, with the majority linked to concurrent nitrate use or pre-existing severe cardiovascular disease 10. Potent CYP3A4 inhibitors (ritonavir, ketoconazole, itraconazole) increase sildenafil AUC by 1,000% and 300% respectively, mandating a maximum dose of 25 mg per 48 hours 3.

Focused Physical Examination

A brief genital exam screens for Peyronie plaques, phimosis, or testicular atrophy. The AUA's 2018 ED guideline recommends this as standard practice: "A focused physical examination including genital, digital rectal, and cardiovascular assessment should be performed" 11.

Follow-Up at 4 to 8 Weeks

The first follow-up assesses efficacy, tolerability, and hemodynamic safety. Most men need 6 to 8 attempts before reliable efficacy is established 1.

Efficacy Assessment

In Goldstein et al.'s landmark 1998 trial (N=532), sildenafil improved erections in 69% of all attempts versus 22% for placebo across a dose range of 25 to 100 mg 1. Use a validated tool like the International Index of Erectile Function (IIEF-5) at baseline and at this visit. A 4-point increase on the IIEF-5 is the minimum clinically important difference 12.

Side Effect Review

Common adverse events in clinical trials: headache (16%), flushing (10%), dyspepsia (7%), nasal congestion (4%), and transient visual disturbance described as a blue-green color tint (3%) 1. The visual effect results from weak inhibition of PDE6 in retinal photoreceptors. It is dose-dependent and typically resolves within hours.

Blood Pressure Recheck

Repeat seated blood pressure. If the patient has been started on a new antihypertensive or alpha-blocker since baseline, reassess the interaction window.

Ongoing Monitoring: Every 6 to 12 Months

Once sildenafil is working and well-tolerated, the monitoring burden drops. But it does not disappear.

Annual Metabolic Panel

Repeat fasting lipids, HbA1c, and renal function annually. ED often precedes a cardiovascular event by 3 to 5 years. In the COBRA trial, men with ED and no known cardiovascular disease had a 65% higher rate of coronary events over a median follow-up of 4.4 years 13. The annual lab panel is not just monitoring the drug. It is monitoring the disease that brought the patient to the drug.

Testosterone Re-check

If the initial testosterone was borderline (300 to 400 ng/dL), repeat at 12 months. Aging-related testosterone decline averages 1 to 2% per year after age 30 14. A man who responded well to sildenafil initially but reports declining efficacy at 12 to 18 months should have testosterone rechecked before dose escalation.

Vision and Hearing Screening

Post-marketing surveillance identified rare cases of non-arteritic anterior ischemic optic neuropathy (NAION) in sildenafil users 15. The FDA label carries a warning, though causality remains unproven. Sudden hearing loss has also been reported 3. At each follow-up, ask about any changes in vision (especially unilateral vision loss) or hearing. Any positive report warrants immediate discontinuation and specialist referral.

Cardiovascular Reassessment

If the patient develops new chest pain, exertional dyspnea, or syncope between visits, sildenafil should be held and cardiac evaluation repeated before resuming. The Princeton Consensus panel emphasized that risk classification is not static: "Cardiovascular risk category should be reassessed at each visit" 9.

Special Populations Requiring Closer Monitoring

Not every patient fits the standard 6-to-12-month schedule. Several groups need tighter surveillance.

Men Over 65

Sildenafil plasma levels are 40% higher in men aged 65 and older due to decreased hepatic clearance 3. Start at 25 mg. Monitor blood pressure at the first follow-up with particular attention to orthostatic changes. Polypharmacy risk rises steeply after age 65, and each new medication warrants a fresh interaction check.

Men with Diabetes

PDE5 inhibitor response rates are lower in men with diabetes. A meta-analysis of 14 trials (N=2,298) found a 63% response rate in diabetic men versus 83% in the general ED population 16. HbA1c should be checked every 6 months in diabetic patients on sildenafil. Glycemic improvement itself can improve ED outcomes.

Men on Antihypertensive Combinations

The additive blood pressure reduction when sildenafil is combined with amlodipine averages an additional 8 mmHg systolic and 7 mmHg diastolic 3. Men on two or more antihypertensives should have seated and standing blood pressure assessed at every visit to detect orthostatic hypotension.

When to Discontinue or Reassess the Prescription

Sildenafil does not require indefinite use. Reassess the need at each annual visit.

Resolved Underlying Cause

If a man achieves euglycemia through weight loss and GLP-1 therapy, or restores testosterone to normal levels through TRT, erectile function may improve enough to trial drug holidays. A structured withdrawal with IIEF-5 scoring at 4 and 8 weeks off therapy provides objective data.

New Contraindications

Any new prescription for nitrates (including nitroglycerin patches or isosorbide) requires immediate and permanent discontinuation of sildenafil. The half-life of sildenafil means at least 24 hours must elapse between the last sildenafil dose and the first nitrate dose 3.

Lack of Response

If a patient has not responded after 8 attempts at the maximum 100 mg dose with proper timing (empty stomach, adequate stimulation), the AUA guideline recommends considering intracavernosal injection therapy, vacuum erection devices, or penile prosthesis referral rather than continuing an ineffective oral agent 11.

Prescribers who track the IIEF-5 score at each visit generate the cleanest decision trail for when to escalate, maintain, or step down therapy.